Hand Hygiene: Why, How, & When?
The purpose of this Standard Operating Procedure (SOP) is to describe the detailed process on how to manage discarded COVID-19 vaccine vials and associated waste after COVID-19 vaccination activities end. The SOP provides clear instructions on how to perform the appropriate treatment and safe dispos...al of these wastes to minimize any associated health risk with consideration to local context.
more
During monitoring and between patients
Always read and follow the instructions and recommendations of the manufacturer`s manual
The device must be cleaned and disinfected after each individual use and, at minimum weekly, prior to use on another patient.
Int J Crit Illn Inj Sci. 2012 May-Aug; 2(2): 82–97.
doi: 10.4103/2229-5151.97273
PMCID: PMC3401822
PMID: 22837896
Communities affected by a disaster often lack basic water
and sanitation facilities. They are likely to be traumatized and
vulnerable to disease. Disruption of familiar practices or the
relocation to new environments can result in a deterioration
in existing hygiene behaviours. This, in turn, wi...ll contribute to
an increased risk of disease transmission and epidemics. This
technical note explains why hygiene promotion is important in
emergencies and describes how to carry it out.
more
UN-Water Global Analysis and Assessment of Sanitation and Drinking-water (GLAAS)
On the appropriate use of gloves with respect to hand hygiene.
This policy brief examines the implications of COVID-19 and the government’s preventative measure for political stability,9 especially in the short to medium term. It argues that in the short term the disease and the preventative measures could make the country less vulnerable to organised politic...al violence and more vulnerable to riots. In the medium and long term, however, vulnerability to both types of violence could increase, depending on the capacity of political forces to instigate and manage conflict and on their willingness to work together.
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more